Osteosarcoma News and Research

RSS

Between two and three percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.

Osteosarcoma is an orphan disease with approximately 1,200 new cases diagnosed in the United States each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group (COG), the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.

Treating the cerebrospinal fluid to protect the brain from chemotherapy's toxic effects

Up to three quarters of patients receiving cancer chemotherapy suffer from "chemo brain" -; a long-term side effect that makes it harder to remember things, maintain attention, and learn new information. When it strikes children, whose brains are still developing, their schoolwork and self-esteem may suffer.

13 Sep 2022

Research identifies unique vulnerabilities in ALT cancers that can serve as novel therapeutic targets

In a study recently published in Cancer Research, a journal of the American Association for Cancer Research, a team of researchers led by C. Patrick Reynolds, M.D., Ph.D., director for the Texas Tech University Health Sciences Center School of Medicine Cancer Center, sought to expand upon his lab's previous research that showed ALT tumors identified by a biomarker known as C-circles share a common biology that confers vulnerabilities to be exploited for cancer therapy.

10 Aug 2022

Inhaled recombinant IL-15 tested in pet dogs with metastatic lung disease from osteosarcoma or melanoma

A protein that the body naturally produces could become an important new immunotherapy drug in the cache of cancer-fighting tools available to oncologists.

9 Jun 2022

Scientists identify the role of phospholipid in maintaining epithelial cellular adhesion

Cells have certain proteins that help them adhere to each other while covering body surfaces and organs. Loss of these identifying proteins could result in cellular progression towards cancer and, subsequently, metastasis.

9 May 2022

Soy molasses and kudzu roots may help fight against pediatric tumors

Soy molasses and kudzu roots contain isoflavonoids with high antioxidant and cytotoxic activity, scientists have discovered.

30 Mar 2022

TTUHSC researcher secures $1.9 million grant to investigate vulnerabilities in ALT cancers

The National Cancer Institute, part of the National Institutes of Health, recently awarded a five-year, $ $1.9 million grant to C. Patrick Reynolds, M.D., Ph.D., director for the School of Medicine Cancer Center at the Texas Tech University Health Sciences Center.

23 Mar 2022

Study links phthalates to higher incidence of specific childhood cancers

In a first-of-its-kind study, research from the University of Vermont Cancer Center has linked phthalates, commonly called the "everywhere chemical," to higher incidence of specific childhood cancers.

16 Mar 2022

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Stand Up To Cancer and Zentalis Pharmaceuticals, Inc. today announced that Zentalis will contribute $1 million to the SU2C Catalyst program to support research that investigates the use of certain small molecule inhibitors for treating a variety of cancer types.

15 Mar 2022

Penn Medicine receives $12.3 million NIH grant to study FLASH radiotherapy for cancer

With more than $12 million in new funding from the National Institutes of Health, the Abramson Cancer Center at the University of Pennsylvania will build on its preclinical research of an emerging form of radiation that provides ultra-fast doses-;of under a second, compared to several minutes with conventional radiation-;and shows promise of greater protection of normal tissue, thereby minimizing toxic effects to the body.

1 Mar 2022

Antibody combination produces a synergistic response in difficult-to-treat pediatric cancers

A combination of anti-cancer antibodies produced a powerfully synergistic response in two hard-to-treat pediatric cancers, according to a new study, in mice, led by researchers at the Stanford University School of Medicine.

19 Jan 2022

The antiviral function of BET protein against SARS-CoV-2 infection

Considering the past shreds of evidence on BRD2 and BRD4 associated with viral infections, researchers have recently evaluated the function of all relevant BET proteins during COVID-19 infection.

17 Nov 2021

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

A short report recently published in the Journal of Infectious Diseases demonstrates how spike mutations L452R and E484Q found in the variant B.1.617.1 of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) each confer modestly diminished sensitivity to Pfizer-BioNTech (BNT162b2) mRNA vaccine-elicited antibodies – with combined mutations having a similar impact as either one of them alone.

19 Jul 2021

Specialized protein appears to regulate key step in cancer metastasis

Researchers have identified a specialized protein that appears to help prevent tumor cells from entering the bloodstream and spreading to other parts of the body.

12 Jul 2021

Combination of SFRP2 and PD-1 immunotherapy halts aggressive metastatic cancer in preclinical model

In a cancer that has not seen new targeted therapies for over 20 years, MUSC Hollings Cancer Center researcher and oncologist Nancy Klauber-DeMore, M.D., is pioneering new discoveries.

22 Jun 2021

New potential target for treating metastasized oral malignant melanoma in dogs

Scientists have shown that the biological molecule PD-L1 is a potential target for the treatment of metastasized oral malignant melanoma in dogs.

23 Apr 2021

Cognitive outcomes in survivors of childhood cancers have been largely understudied

In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstream effects on education, employment, and income.

23 Apr 2021

New technology shows encouraging results for treating osteosarcoma

A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues.

13 Apr 2021

Osteosarcoma News and Research

Further Reading